. Author manuscript; available in PMC: 2023 Mar 24.

Published in final edited form as: ACS Biomater Sci Eng. 2020 Nov 20;8(10):4140–4152. doi: 10.1021/acsbiomaterials.0c01313

Table 1.

Mass Loading, Release, and Activity of IgA2 Antibody in Polymer-Coated Porous Si Particle Formulations

polymer coating	dissolution medium^a	intended release region	IgA2 loading^b (%)	release 3h @ pH 6.8/7.4^c(%)	preserved activity^d (%)
Eudragit S100	SGF→PBS	colon (pH >7)	29 ± 1	70 ± 7	44 ± 10
Eudragit L100	SGF→PBS	small intestine (pH > 5.5)	29 ± 1	61 ± 2	21 ± 6
	SGF→FasSIF			48 ± 2	32 ± 13
Eudragit L30 D-55	SGF→PBS	small intestine (pH > 5.5)	31 ± 2	56 ± 2	20 ± 6
	SGF→FasSIF			41 ± 3	24 ± 11

SGF is simulated gastric fluid, pH = 1.2; PBS is phosphate buffered saline solution, pH 7.4; FasSIF is fasting state simulated intestinal fluid, pH = 6.8.

Mass loading of IgA2 protein in the porous Si carrier, prior to polymer coating; defined as (mass of IgA2)/(mass of IgA2 + pSi carrier), given as a percentage. Errors are 3 SD.

Percent by mass of IgA2 released from the particle formulation into the indicated release medium, after 3 h of exposure. Measured by BCA assay. Errors given are 3 SD.

Activity of IgA2 measured by both ELISA and HIV neutralization assay as percent of total IgA2 released, after 3 h of exposure to the pH 6.8/7.4 solution, corresponding to the 5 h time point in Figure 2. Errors given are 3 SD.